Short Reports


, Volume 73, Issue 1, pp 95-96

First online:

A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness

  • Teruo OkumaAffiliated withDepartment of Psychiatry, Tohoku University School of Medicine
  • , Kazutoyo InanagaAffiliated withDepartment of Psychiatry, Kurume University School of Medicine
  • , Saburo OtsukiAffiliated withDepartment of Psychiatry, Okayama University School of Medicine
  • , Keisuke SaraiAffiliated withDepartment of Psychiatry, Hiroshima University School of Medicine
  • , Ryo TakahashiAffiliated withDepartment of Psychiatry, Nagasaki University School of Medicine
  • , Hidefumi HazamaAffiliated withDepartment of Psychiatry, Tottori University School of Medicine
  • , Atsuyoshi MoriAffiliated withDepartment of Psychiatry, Toho University School of Medicine
  • , Shôsuke WatanabeAffiliated withDepartment of Psychiatry, Kawasaki Medical School

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


A preliminary double-blind controlled study on the prophylactic effect of carbamazepine on recurrent manic-depressive psychotics was conducted with 22 patients using an inert placebo in ten subjects as a control drug. Carbamazepine in the dosage of 200–600 mg was administered for 1 year. Among the 22 carbamazepine subjects, carbamazepine was found to be effective in 60% of the cases and inert placebo in 22.2% (U-test, P<0.10). It is suggested that carbamazepine is a useful drug for the prophylaxis of manic-depressive illness.

Key words

Carbamazepine Prophylaxis Manic-depressive psychosis Double-blind controlled trial